News and Media

A new pair of studies from Yale School of Public Health suggests that when a parent is living with dementia or depression, the consequent financial stress becomes a hidden source of emotional turmoil for millions of U.S. families.

In the field of stroke research, Yale works to bridge the gap between preclinical and clinical, increasing the likelihood that new treatments work in patients.

Researchers discovered a protective mechanism used by the brain to mitigate calcium dysfunction, a risk factor for neurodegeneration.

“It would be interesting to see how the gluteus maximus changes in people with better or worse glucose control or if other chronic conditions impact the muscle in the same way,” adds Richard Marottoli, MD, geriatrician at Yale Medicine in New Haven, Connecticut, who wasn’t involved in the study.

Published in npj Parkinson's Disease, new research looked at prevalence and risk factors for RBD among 462 people with IBD. With Brian Koo, MD.

Now a simple symptoms tool, based on a recent study published in the journal Multiple Sclerosis and Related Disorders, may be an effective way to help identify bladder symptoms related to MS progression—providing the first step for someone with MS to get the treatment and relief they need. With Erin Longbrake, MD, PhD.

Driven in part by frustrations with the medical system, more and more Americans are seeking advice from AI. Last year, about 1 in 6 adults — and about a quarter of adults under 30 — used chatbots to find health information at least once a month, according to a survey from KFF, a health policy research group.

During an interview on the Health & Veritas podcast, Thomas Gill describes why physical activity remains important as we age.

Autoreactive B-cells contribute to the onset and progression of generalized myasthenia gravis (gMG) through their role in autoantibody production. Targeting these cells, monoclonal antibody inebilizumab (Uplizna; Amgen), an FDA-approved treatment for neuromyelitis optica spectrum disorder, is currently being investigated in the phase 3 MINT trial (NCT04524273) as a potential therapy for patients with gMG.